Dianthus Therapeutics, Inc.
DNTH
주식 순위
#3781
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
주가
$78.21
시가총액
$4.37B
변동 (1일)
-0.69%
변동 (1년)
123.27%
국가
US
거래 Dianthus Therapeutics, Inc. (DNTH)
카테고리
Healthcare
Dianthus Therapeutics, Inc. (DNTH)의 주가 이력
최고 종가: $80.78 (2026-10-01 기준)
최저 종가: $225.69 (2018-06-01 기준)
최저 종가: $225.69 (2018-06-01 기준)
Dianthus Therapeutics, Inc.의 주가 이력 (2018 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | 74.03% |
| 2025 | 79.27% |
| 2024 | 158.65% |
| 2023 | -30.65% |
| 2022 | -83.63% |
| 2021 | -32.46% |
| 2020 | -46.40% |
| 2019 | 100.40% |
| 2018 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $518.20 | 21.57% |
US
|
|
| $243.77 | 786.76% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $879.20 | 5.32% |
NL
|
|
| $752.87 | 7.40% |
CH
|
